Disclosed is a use of a microparticulate formulation of a therapeutic agent, wherein the microparticulate formulation comprises a plurality of microparticles and the therapeutic agent comprises a dihydropyridine L-type voltage dependent calcium channel inhibitor selected from the group consisting of nisolipine, nicardipine, difedipine and nimodipine, and a pharmaceutically acceptable carrier comprising between 0% to 5% hyaluronic acid in the manufacture of a medicament for treating a delayed complication associated with a brain injury in a mammal in need thereof, wherein the brain injury includes interruption of at least one cerebral artery in subarachnoid space, wherein the medicament is a site-specific, sustained release pharmaceutical composition and is for use in a dosage regime comprising: (a) administering a therapeutic amount of the pharmaceutical composition locally by a means for administration of the therapeutic amount of the pharmaceutical composition at a site of administration, wherein: (1) the microparticulate formulation of the pharmaceutical composition is flowable； (2) the microparticles are of uniform size distribution； (3) each microparticle comprises a matrix； (4) the L-type voltage dependent calcium channel inhibitor is dispersed throughout each microparticle； (5) the L-type voltage dependent calcium channel inhibitor is released from the microparticulate formulation by gradual release over an extended period of time； (6) cerebrospinal fluid (CSF) concentration of the L-type voltage dependent calcium channel inhibitor remains in therapeutic range while plasma concentration of the L-type voltage dependent calcium channel inhibitor is below therapeutic range during therapy, thereby circumventing unwanted side effects associated with systemic delivery； and (7) the therapeutic amount that contacts and flows around the cerebral artery in the subarachnoid space is effective in reducing signs or symptoms of at least one delayed complication associated
